Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Cyclin-Dependent Kinases
  • Flavonoids
  • Piperidines
  • Stomach Neoplasms

abstract

  • Flavopiridol administered as a single agent for 72 hours every 14 days is inactive in the treatment of gastric cancer. The drug also induced an unexpected higher incidence of vascular thrombosis and fatigue than was anticipated from the phase I trials. Future development of flavopiridol will depend on other doses and schedules in combination with chemotherapy.

publication date

  • April 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11283131

Additional Document Info

start page

  • 1985

end page

  • 92

volume

  • 19

number

  • 7